NCT00002556View on ClinicalTrials.gov

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

PHASE3CompletedINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

July 31, 1994

Primary Completion Date

January 31, 2006

Conditions
Stage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
Interventions
DRUG

vincristine sulfate

Given IV

DRUG

carmustine

Given IV

DRUG

melphalan

Given PO

DRUG

cyclophosphamide

Given IV

DRUG

prednisone

Given PO

BIOLOGICAL

recombinant interferon alfa-2b

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00002556 - Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma | Biotech Hunter | Biotech Hunter